Montelukast/Bepotastine besilate

孟鲁司特/苯磺贝他斯汀

Report date: 2022/01/24 14:07:46

Base Information

Drug NameMontelukast/Bepotastine besilate
Drug Alias NameMontelukast sodium/Bepotastine besilate - Windlas BiotechBepotastine besilate/montelukast - Windlas BiotechBepotastine besilate/montelukast sodium - Windlas BiotechMontelukast/bepotastine besilate - Windlas Biotech
ClassificationSmall molecules
Mechanisms of ActionHistamine H1 receptor antagonistsCysteinyl leukotriene receptor 1 antagonists
TargetsCysteinyl leukotriene receptor 1Histamine H1 receptor
Therapy Area/IndicationsRhinitis, Allergic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes MontelukastBepotastine besilate
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesWindlas Biotech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWindlas Biotech Ltd
Inactive CompaniesN/A
Active IndicationsRhinitis, Allergic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A